1. Home
  2. VPG vs COAG Comparison

VPG vs COAG Comparison

Compare VPG & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vishay Precision Group Inc.

VPG

Vishay Precision Group Inc.

HOLD

Current Price

$92.67

Market Cap

1.4B

Sector

Technology

ML Signal

HOLD

Logo Hemab Therapeutics Holdings Inc. Common Stock

COAG

Hemab Therapeutics Holdings Inc. Common Stock

N/A

Current Price

$46.89

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VPG
COAG
Founded
2009
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
2010
2026

Fundamental Metrics

Financial Performance
Metric
VPG
COAG
Price
$92.67
$46.89
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$53.50
N/A
AVG Volume (30 Days)
452.9K
379.1K
Earning Date
05-12-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$307,202,000.00
N/A
Revenue This Year
$7.21
N/A
Revenue Next Year
$6.92
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.22
N/A
52 Week Low
$25.58
$27.47
52 Week High
$151.78
$52.15

Technical Indicators

Market Signals
Indicator
VPG
COAG
Relative Strength Index (RSI) 40.81 57.91
Support Level $37.49 $43.05
Resistance Level $150.08 $51.50
Average True Range (ATR) 8.14 4.55
MACD -1.60 -0.32
Stochastic Oscillator 39.83 53.66

Price Performance

Historical Comparison
VPG
COAG

About VPG Vishay Precision Group Inc.

Vishay Precision Group Inc manufactures and markets sensors and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.

About COAG Hemab Therapeutics Holdings Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Share on Social Networks: